Olfactory Neurogenic Tumor

subtype

Identifier: CI-CAN-00001302
Entity page: /cancer/olfactory-neurogenic-tumor ↗
Edges: 17

Neighbours: 3 drugs14 trials
Drawn: 17 of 17 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Olfactory Neurogenic Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived3 of 3
→ investigated in trials for	Enasidenibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Olfactory Neurogenic Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibuprofensmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants

Olfactory Neurogenic Tumor studied in …STUDIED_INderived14 of 14show fewer
→ studied in	NCT06479811Phase 1 · recruiting [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04755205recruiting A Natural History Study of Children and Adults With Olfactory Neuroblastoma · condition mapped ONTOLOGY_EXACT · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07527169Phase 2 · not yet recruiting A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma · condition mapped CURATED_BROADER · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06607692Phase 1/Phase 2 · recruiting Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04087902active not recruiting Long-Term Longitudinal QoL in Patients Undergoing EEA · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04081701Phase 4 · recruiting 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05012098Phase 2 · completed Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). · condition mapped ONTOLOGY_EXACT · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07072143recruiting An International Study on Pediatric Patients With Rare Tumors. · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06308575Phase 2 · withdrawn A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma · condition mapped CURATED_BROADER · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06255210Phase 2 · recruiting Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) · condition mapped ONTOLOGY_EXACT · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01586767NA · unknown Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02580136withdrawn Esthesioneuroblastoma: Outcomes After Treatment · condition mapped ALIAS · 14 trials mapped (10 active)	—	—	Olfactory Neuroblastoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains